Cryoport, Inc.

Informe acción NasdaqCM:CYRX

Capitalización de mercado: US$796.0m

Cryoport Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Cryoport han disminuido a una tasa media anual de -32.6%, mientras que en la industria Life Sciences los beneficios crecieron en un 16.4% anualmente. Los ingresos han ido creciendo a una tasa media de 41.6% al año.

Información clave

-32.6%

Tasa de crecimiento de los beneficios

-28.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Life Sciences 21.5%
Tasa de crecimiento de los ingresos41.6%
Rentabilidad financiera-20.4%
Margen neto-46.1%
Próxima actualización de resultados07 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk

Apr 15
Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk

Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 15
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Cryoport Tanks On Chilling Results And Bad Decisions

Mar 14

Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Mar 10
Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Fewer Investors Than Expected Jumping On Cryoport, Inc. (NASDAQ:CYRX)

Jan 15
Fewer Investors Than Expected Jumping On Cryoport, Inc. (NASDAQ:CYRX)

Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Oct 06
Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term

Jul 23
Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term

Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity

Jul 12
Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity

Is Cryoport (NASDAQ:CYRX) A Risky Investment?

Jun 13
Is Cryoport (NASDAQ:CYRX) A Risky Investment?

Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price

Mar 06
Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price

Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially

Nov 07
Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially

Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Sep 23
Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Cryoport: A Rare Investing Opportunity

Sep 22

Cryoport enters into strategic relationship with Takeda's BioLife Plasma Services

Sep 08

Cryoport: Rapid Growth Is Great, But Shares Look Overpriced

Jul 30

Cryoport: To Resume Aggressive Growth

May 11

Cryoport: An Industry Leader Basking In Industry Tailwinds

Apr 15

Cryoport: Risky Investment With Upside Potential

Apr 01

Cryoport: More Growth Going Into New Year 2022

Dec 29

Is Cryoport, Inc. (NASDAQ:CYRX) Trading At A 49% Discount?

Dec 05
Is Cryoport, Inc. (NASDAQ:CYRX) Trading At A 49% Discount?

What Is Cryoport, Inc.'s (NASDAQ:CYRX) Share Price Doing?

Nov 09
What Is Cryoport, Inc.'s (NASDAQ:CYRX) Share Price Doing?

Is Cryoport (NASDAQ:CYRX) Using Too Much Debt?

Oct 17
Is Cryoport (NASDAQ:CYRX) Using Too Much Debt?

Cryoport: The Golden Stock

Oct 08

Cryoport: Unfairly Punished, Valuation Update Shows 45% Upside

Oct 01

Cryoport: Best Price-Positioned Medical Services Stock, As Seen By Market-Makers

Jul 01

Is Cryoport, Inc. (NASDAQ:CYRX) Trading At A 47% Discount?

Jun 08
Is Cryoport, Inc. (NASDAQ:CYRX) Trading At A 47% Discount?

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Cryoport. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NasdaqCM:CYRX Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Dec 23233-10814018
30 Sep 23236-5513418
30 Jun 23241-4712817
31 Mar 23248-3812516
31 Dec 22237-4511816
30 Sep 22233-29610915
30 Jun 22230-29710315
31 Mar 22222-2939816
31 Dec 21223-2849817
30 Sep 21215-769316
30 Jun 21169-787715
31 Mar 21122-776112
31 Dec 2079-75479
30 Sep 2040-22287
30 Jun 2038-23366
31 Mar 2037-20335
31 Dec 1934-18314
30 Sep 1930-20313
30 Jun 1926-9202
31 Mar 1922-9182
31 Dec 1820-10172
30 Sep 1817-10162
30 Jun 1815-9152
31 Mar 1813-9141
31 Dec 1712-8131
30 Sep 1711-10121
30 Jun 1710-10111
31 Mar 179-12111
31 Dec 168-13111
30 Sep 167-12111
30 Jun 166-12111
31 Mar 166-15100
31 Dec 156-1690
30 Sep 155-1580
30 Jun 154-1670
31 Mar 154-1260
31 Dec 144-1060
30 Sep 143-1060
30 Jun 143-2150
31 Mar 143-2050
31 Dec 132-2050
30 Sep 132-2050
30 Jun 131-650

Ingresos de calidad: CYRX actualmente no es rentable.

Margen de beneficios creciente: CYRX actualmente no es rentable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CYRX no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 32.6% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CYRX en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: CYRX no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Life Sciences (-9.3%).


Rentabilidad financiera

Alta ROE: CYRX tiene una rentabilidad financiera negativa (-20.36%), ya que actualmente no es rentable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target